Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Autolus Therapeutics (NASDAQ:AUTL) stock has reached a new 52-week low, trading at $1.87, as the biopharmaceutical company faces a challenging market environment. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 13.69, though it’s currently trading below its Fair Value. This latest price level reflects a significant downturn over the past year, with the stock experiencing a substantial 1-year change, plummeting by -69.15%. Investors are closely monitoring Autolus Therapeutics as it navigates through the volatility of the biotech sector, which has been marked by rapid shifts in investor sentiment and regulatory landscapes. While the company holds more cash than debt on its balance sheet, analysts have revised their earnings expectations downward for the upcoming period. The company’s journey to this 52-week low underscores the broader industry’s hurdles and the high-risk nature of biopharmaceutical investments. For deeper insights into AUTL’s financial health and 10+ additional ProTips, visit InvestingPro.
In other recent news, Autolus Therapeutics has shared significant developments concerning their CAR-T cell therapy, AUCATZYL®. The company announced findings from the FELIX study, published in the New England Journal of Medicine, which revealed a 76.6% complete remission rate in adult patients with B-cell Acute Lymphoblastic Leukemia treated with their therapy. The study, involving 153 patients, highlighted that the therapy was associated with a low incidence of severe immune-related toxicity. Additionally, Autolus presented data at the 2025 Tandem Meetings, indicating that AUCATZYL® might reduce healthcare costs due to fewer adverse events compared to other CAR-T therapies. Further presentations showcased AUCATZYL®’s effectiveness, demonstrating higher overall response rates and longer survival compared to standard therapies. Autolus is also pursuing regulatory approval for AUCATZYL® in Europe and the UK, with submissions accepted earlier this year. These developments underscore Autolus’s ongoing efforts to enhance cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.